

# Darron R Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/424742/publications.pdf>

Version: 2024-02-01

53  
papers

2,883  
citations

304743

22  
h-index

214800

47  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2909  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. <i>Journal of Infectious Diseases</i> , 2009, 199, 926-935.	4.0	528
2	A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent Women. <i>Journal of Infectious Diseases</i> , 2005, 191, 182-192.	4.0	364
3	Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. <i>Clinical Infectious Diseases</i> , 2016, 63, 519-527.	5.8	360
4	Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. <i>Hum Vaccin</i> , 2009, 5, 696-704.	2.4	184
5	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1997-2008.	2.5	137
6	Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction. <i>Pediatrics</i> , 2012, 130, e249-e256.	2.1	111
7	Association of Condom Use, Sexual Behaviors, and Sexually Transmitted Infections With the Duration of Genital Human Papillomavirus Infection Among Adolescent Women. <i>JAMA Pediatrics</i> , 2006, 160, 151.	3.0	98
8	Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 287-296.	2.5	98
9	Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. <i>Journal of Medical Virology</i> , 2001, 64, 550-559.	5.0	97
10	The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay. <i>Hum Vaccin</i> , 2011, 7, 230-238.	2.4	97
11	Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. <i>Vaccine</i> , 2004, 22, 2936-2942.	3.8	77
12	Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1585-1594.	2.5	73
13	Prevalence and Persistence of Cervical Human Papillomavirus Infection in HIV-Positive Women Initiating Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 274-282.	2.1	54
14	Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. <i>Pediatrics</i> , 2019, 143, .	2.1	45
15	Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. <i>Clinical Infectious Diseases</i> , 2016, 63, 1281-1287.	5.8	44
16	Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. <i>Vaccine</i> , 2014, 32, 5880-5887.	3.8	38
17	Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration. , 1997, 53, 185-188.		33
18	Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 61-69.	4.5	30

#	ARTICLE	IF	CITATIONS
19	Episodic detection of human papillomavirus within a longitudinal cohort of young women. <i>Journal of Medical Virology</i> , 2015, 87, 2122-2129.	5.0	29
20	Distribution of Human Papillomavirus Types in Cervicovaginal Washings From Women Evaluated in a Sexually Transmitted Diseases Clinic. <i>Sexually Transmitted Diseases</i> , 2002, 29, 763-768.	1.7	27
21	Association of Chlamydia trachomatis Infection With Redetection of Human Papillomavirus After Apparent Clearance. <i>Journal of Infectious Diseases</i> , 2013, 208, 1416-1421.	4.0	27
22	Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1962-1969.	3.3	27
23	Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 10, 100202.	4.5	27
24	Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. <i>Vaccine</i> , 2021, 39, 2224-2236.	3.8	25
25	The human papillomavirus type 11 E1 <sup>E4</sup> protein is a transglutaminase 3 substrate and induces abnormalities of the cornified cell envelope. <i>Virology</i> , 2006, 345, 290-298.	2.4	23
26	Oral Human Papillomavirus Is Common in Individuals with Fanconi Anemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 864-872.	2.5	23
27	A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women. <i>BMC Infectious Diseases</i> , 2019, 19, 352.	2.9	19
28	Detection of human papillomavirus types 6 and 11 E4 gene products in condylomata acuminatum. <i>Journal of Medical Virology</i> , 1991, 34, 20-28.	5.0	18
29	High-grade dysplasia in genital warts from two patients infected with the human immunodeficiency virus. <i>Journal of Medical Virology</i> , 1998, 54, 69-73.	5.0	17
30	Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women. <i>Journal of Medical Virology</i> , 2013, 85, 1786-1793.	5.0	16
31	Knowledge of Cervical Cancer and Acceptability of Prevention Strategies Among Human Papillomavirus-Vaccinated and Human Papillomavirus-Unvaccinated Adolescent Women in Eldoret, Kenya. <i>BioResearch Open Access</i> , 2019, 8, 139-145.	2.6	15
32	Prevalence of Human Papillomavirus Infection in Young Women Receiving the First Quadrivalent Vaccine Dose. <i>JAMA Pediatrics</i> , 2012, 166, 774.	3.0	14
33	Invasive cervical cancers in the United States, Botswana and Kenya: HPV type distribution and health policy implications. <i>Infectious Agents and Cancer</i> , 2016, 11, 56.	2.6	13
34	Redetection of human papillomavirus type 16 infections of the cervix in mid-adult life. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 75-79.	4.5	12
35	Invasive cervical cancers from women living in the United States or Botswana: differences in human papillomavirus type distribution. <i>Infectious Agents and Cancer</i> , 2014, 9, 22.	2.6	11
36	Detection and Concentration of Plasma Aflatoxin Is Associated With Detection of Oncogenic Human Papillomavirus in Kenyan Women. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.9	11

#	ARTICLE	IF	CITATIONS
37	DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women. <i>Sexually Transmitted Infections</i> , 2014, 90, 64-69.	1.9	9
38	Persistence of oncogenic and non-oncogenic human papillomavirus is associated with human immunodeficiency virus infection in Kenyan women. <i>SAGE Open Medicine</i> , 2020, 8, 205031212094513.	1.8	7
39	Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines. <i>Vaccine</i> , 2021, 39, 2214-2223.	3.8	7
40	Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. <i>Vaccine</i> , 2019, 37, 6832-6841.	3.8	6
41	Longer duration of anti-retroviral therapy is associated with decreased risk of human papillomavirus detection in Kenyan women living with HIV. <i>International Journal of STD and AIDS</i> , 2021, 32, 1212-1220.	1.1	6
42	Detection of human papillomavirus L1 protein in condylomata acuminata from adults with defects in cell-mediated immunity. <i>Journal of Medical Virology</i> , 1993, 41, 79-84.	5.0	4
43	Temporal and histologic relationships of proliferating cell nuclear antigen and human papillomavirus type 11 in the mouse xenograft system. , 1996, 48, 108-113.		4
44	Intracellular Expression Patterns of the Human Papillomavirus Type 59 E1 <sup>E4</sup> Protein in COS Cells, Keratinocytes, and Genital Epithelium. <i>Intervirology</i> , 2004, 47, 321-327.	2.8	4
45	Detection of types of HPV among HIV <sup>+</sup> infected and HIV <sup>-</sup> uninfected Kenyan women undergoing cryotherapy or loop electrosurgical excision procedure. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 279-286.	2.3	4
46	Human Papillomavirus Oral- and Sero- Positivity in Fanconi Anemia. <i>Cancers</i> , 2021, 13, 1368.	3.7	3
47	Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women. <i>Tumour Virus Research</i> , 2022, 13, 200236.	3.8	3
48	Clarification on the Impact of Cervarix Vaccination on Human Papillomavirus Infection and Cervical Cancer in the United Kingdom. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 00-00.	3.3	2
49	Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration. , 1997, 53, 185.		1
50	Association of detection of aflatoxin in plasma of Kenyan women with increased detection of oncogenic HPV.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5530-5530.	1.6	1
51	AMPATH Oncology: Baseline HPV detection in Kenyan women enrolled in a longitudinal study of modifiable factors predicting cervical dysplasia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5533-5533.	1.6	0
52	Comparison of HPV detection in HIV-infected and HIV-uninfected Kenyan women with or without cervical dysplasia.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17015-e17015.	1.6	0
53	A community-based approach to cervical cancer prevention in western Kenya: An AMPATH feasibility project. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211021.	1.8	0